<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493465</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ABR33T</org_study_id>
    <nct_id>NCT02493465</nct_id>
  </id_info>
  <brief_title>Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study</brief_title>
  <official_title>Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Urologia e Nefrologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Urologia e Nefrologia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open label, single-center study, in kidney transplant recipients with
      stable renal function for 12 and 120 months after transplantation, that are in use use of
      calcineurin inhibitors, azathioprine, and prednisone. The prevalence of left ventricular
      hypertrophy will be investigated before and after conversion of azathioprine to everolimus.

      This study will evaluate as primary objectives: the prevalence of left ventricular mass
      hypertrophy in renal transplant recipients with azathioprine therapy. And assess the ability
      of everolimus to reduce left ventricular mass after conversion from Azathioprine, using
      sensitive methods such as MRI. And as secondaries objectives: Renal function (measured GFR)
      at 3 and 6 and 12 months after conversion, number and severity of episodes of acute rejection
      proven by biopsy, and the proteinuria at 3, 6 and 12 months after conversion.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression of left ventricular hypertrophy</measure>
    <time_frame>12 months</time_frame>
    <description>Progression of left ventricular hypertrophy will be mesure by MIR and echocardiography (systolic and end-diastolic diameter of the left ventricle, interventricular septum thickness in end diastole, thickness of the ventricular posterior wall of the left ventricle in end-diastole, left ventricular mass, percentage of left ventricular ejection fraction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>renal function</measure>
    <time_frame>3,6, 12 months</time_frame>
    <description>GFR (creatinina clearance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proteinuria</measure>
    <time_frame>3,6, 12 months</time_frame>
    <description>24h Proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute rejection episodies</measure>
    <time_frame>12 months</time_frame>
    <description>clinical and biopsy if acute rejection suspected</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Left Ventricular Hypertrophy</condition>
  <arm_group>
    <arm_group_label>LVH everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Progression of left ventricular hypertrophy in recipients of kidney transplant after conversion of immunossupression from azathioprine to everolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.</description>
    <arm_group_label>LVH everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years (black and white subjects);

          -  Kidney transplant recipients of living donor or deceased with creatinine clearance
             (measured / estimated) &gt; 50 ml /L for at least 12 months, receiving azathioprine with
             or without calcineurin inhibitor with or without prednisone.

        Exclusion Criteria:

          -  The subject, in the opinion of the investigator, is not able to complete the study
             protocol;

          -  Multiple organ transplant recipient;

          -  Pregnant women

          -  Breastfeeding and childbearing age without contraceptive method

          -  Test for Positive immunodeficiency virus (HIV)

          -  Treatment of acute rejection in the last 3 months

          -  Glomerulonephritis new relapse

          -  New or polyomavirus nephropathy

          -  protein / creatinine ≤ 150 mg / mmol or 24h proteinuria&gt; 500mg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto de Urologia e Nefrologia</name>
      <address>
        <city>São José do Rio Preto</city>
        <state>São Paulo</state>
        <zip>15015-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Abbud, MD.PhD</last_name>
      <phone>551740099165</phone>
      <email>mabbud@terra.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Ananda F Calori</last_name>
      <phone>551740099167</phone>
      <email>estudos@iun.com.br</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <last_update_submitted>July 8, 2015</last_update_submitted>
  <last_update_submitted_qc>July 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Urologia e Nefrologia</investigator_affiliation>
    <investigator_full_name>MARIO ABBUD FILHO</investigator_full_name>
    <investigator_title>MD PHD</investigator_title>
  </responsible_party>
  <keyword>everolimus</keyword>
  <keyword>left ventricular hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

